Chemical platform to produce covalent biologics
Chemical platform to produce covalent biologics
批准号:
10511039
负责人:
Alexander V Statsyuk
金额:
$23.59万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-01 至 2024-08-31
关键词:
AddressAmino AcidsAmino Acyl Transfer RNAAmino Acyl-tRNA SynthetasesAnti-Inflammatory AgentsAntibodiesBiologicalBiological AssayBiological ModelsBiological ProductsBiologyCellsChemicalsChemistryCysteineDataEngineeringFutureHistorically Black Colleges and UniversitiesHormonesImmune checkpoint inhibitorImmunoglobulin FragmentsImmunologyIn VitroInjectionsInstructionInsulinKRAS2 geneKnowledgeLiteratureMetabolicMethodsModalityMonoclonal AntibodiesMusMutagenesisNaturePharmaceutical PreparationsPharmacologyPopulationPositioning AttributePriceProductionProtein BiochemistryProteinsRas InhibitorReactionReportingResearchScienceStructure-Activity RelationshipStudentsSurfaceSystemTechnologyTestingTherapeuticTherapeutic UsesTranslatingUnderrepresented MinorityUniversitiesWorkanakinraanalogbaseclinical candidatecovalent bondcrosslinkdrug discoveryhigh riskhigh throughput screeninghuman diseaseimprovedin vivonew technologynovelnovel therapeuticspreventprogrammed cell death protein 1programsprotein aggregationpublic health relevancereceptorscreeningsmall moleculetherapeutic cytokinestherapeutic proteinvirtual
中文摘要
项目摘要
拟议研究计划的目标是开发一种化学平台技术,
优化共价生物制剂-一种新的治疗方式。生物药品是药品的主要组成部分,
然而,它们的缺点是价格高,需要频繁注射。我们假设
共价生物制剂将具有高得多的效力,并且将需要较低频率的注射。常规
产生共价生物制剂的方法依赖于非天然氨基酸诱变,但该方法不是
生产能力降低,并遭受蛋白质产量降低的问题。拟议的化学技术旨在
通过提高共价生物产量来克服这些挑战,允许快速合成和测试数百种
共价生物药物,并允许几乎无限数量的共价弹头,可以
安装在蛋白质表面。这是一个高风险的建议,没有任何初步数据,按照说明,
PAR-19-254我们最初的探索性研究将集中在开发化学平台和验证它
在基于细胞的研究和免疫学研究中使用免疫检查点抑制剂和抗炎蛋白治疗剂,
vivo.这是一项共同主要研究者提案,涉及休斯顿大学的亚历山大·斯塔西克(擅长
化学和蛋白质生物化学)和维多利亚Mgbemena从草原视图A&M大学(专业知识,
免疫学和小鼠生物学)。Prairie View A&M University属于历史上的黑人大学,
大学,并服务于学生人口谁是科学代表不足的少数民族。
英文摘要
PROJECT SUMMARY
The objective of the proposed research program is to develop a chemical platform technology to produce and
optimize covalent biologics - a new therapeutic modality. Biologic drugs constitute the large sector of drug
discovery, however their downside is a high price and the need for frequent injections. We hypothesize that
covalent biologics will have much higher potency and will need less frequent injections. The conventional
methods to produce covalent biologics rely on unnatural aminoacid mutagenesis but this method is not
throughput and suffer from the reduced protein production yields. The proposed chemical technology aims to
overcome these challenges by improving covalent biologic yield, allowing rapid synthesis and testing of 100s of
covalent biologic drugs in one day, and allowing virtually unlimited number of covalent warheads that can be
installed on the protien surface. This is a high risk proposal without any preliminary data as per instructions in
PAR-19-254. Our initial exploratory studies will focus on developing the chemical platform and validating it
using immune checkpoint inhibitors and anti-inflammatory protein therapeutics in both cell based studies and in
vivo. This is a Co-PI proposal involving Alexander Statsyuk from the University of Houston (expertise in
chemistry and protein biochemistry) and Victoria Mgbemena from the Prairie View A&M University (expertise in
immunology and mouse biology). Prairie View A&M University belongs to historically black colleges and
universities, and serves student population who are underrepresented minorities in science.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemical platform to produce covalent biologics
-
批准号:10688088
-
项目类别:
-
资助金额:$18.34万
-
财政年份:2022
-
负责人:Alexander V Statsyuk
-
依托单位:
Pharmacological Inhibitors of Nedd4 ubiquitin ligase as anticancer therapeutics
-
批准号:9100801
-
项目类别:
-
资助金额:$2.41万
-
财政年份:2015
-
负责人:Alexander V Statsyuk
-
依托单位:
Pharmacological Inhibitors of Nedd4 ubiquitin ligase as anticancer therapeutics
-
批准号:9394058
-
项目类别:
-
资助金额:$26.59万
-
财政年份:2015
-
负责人:Alexander V Statsyuk
-
依托单位:
Pharmacological Inhibitors of Nedd4 ubiquitin ligase as anticancer therapeutics
-
批准号:9302491
-
项目类别:
-
资助金额:$30.14万
-
财政年份:2015
-
负责人:Alexander V Statsyuk
-
依托单位:
海外基金